NMTC earnings analysis
What we found in NMTC's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
NeuroOne delivered $1.97 million of fiscal third-quarter 2026 revenue, up 16% year over year, while product gross margin improved to 59.9% and diluted EPS improved to $(0.28). However, the company remained structurally loss-making, held only approximately $2.0 million of cash and continued to face substantial doubt about its ability to continue as a going concern. The reduction of fiscal 2026 revenue guidance to $9.2 million-$10.5 million, combined with unremediated accounting weaknesses and potential Nasdaq listing risk below $5 million of market value, leaves the overall risk/reward unfavorable.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 16% year over year
- Third-quarter fiscal 2026 revenue was $1.97 million, up 16% from approximately $1.70 million in the prior-year quarter, although modestly below approximately $2.0 million in the prior quarter.
- Gross margin expanded
- Product gross margin improved to 59.9% from 53.2% in the prior quarter and 53.9% in the prior-year quarter, a 6.7- and 6.0-percentage-point expansion, respectively.
- Orders exceeded shipments
- Orders were $2.7 million versus $1.97 million of reported shipments, indicating demand exceeded recognized revenue by approximately $0.73 million.
- Per-share loss narrowed
- Diluted EPS improved to $(0.28) from $(1.08) in the prior-year quarter and $(1.08) in the immediately preceding period, although the company remained loss-making.
- Control remediation is underway
- Management is implementing remediation actions covering shipping-to-revenue reconciliations, documented management reviews, and segregation of duties, but the material weaknesses had not been remediated as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity and going-concern pressure
- The company had cash and cash equivalents of approximately $2.0 million at June 30, 2026, and stated that existing cash, cash equivalents and short-term investments will not be sufficient to fund operating expenses. Management continued to conclude that substantial doubt about going concern existed.
- Shipment timing lowered outlook
- Fiscal 2026 recognized revenue guidance was reduced to $9.2 million-$10.5 million from a prior minimum of $10.5 million because of manufacturing completion and shipment timing. Orders of $2.7 million nevertheless exceeded the quarter's $1.97 million shipments, highlighting conversion and timing risk.
- Unremediated accounting weaknesses
- Disclosure controls and procedures remained ineffective as of June 30, 2026 because of material weaknesses in segregation of duties and revenue-recognition controls. The revenue-control weakness involved purchase-order modifications, shipping documentation and shipment reconciliations and had led to a restatement of the March 31, 2026 interim financial statements.
- Persistent losses require financing
- The company reported an accumulated deficit of $84.4 million as of June 30, 2026 and stated that it expects significant expenses and operating losses for the foreseeable future. Additional equity or debt financing may be required, creating dilution and financing-access risk.
- Potential Nasdaq delisting risk
- A proposed Nasdaq minimum market value of listed securities rule would require at least $5 million and could result in immediate delisting after 30 consecutive trading days below that level, with no cure period. The SEC stay of the rule was noted as of July 29, 2026, but the outcome remained uncertain.
- Supply and distributor dependence
- The company disclosed recent delays in component and raw-material availability that caused product backorders and delayed or prevented timely fulfillment. It also relies on Zimmer for exclusive global brain distribution through 2034, exposing sales to distributor purchase-order and commercialization decisions.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.28
- Gross margin
- 59.9%
What they said about what is next.
Fiscal 2026 recognized revenue guidance is $9.2 million-$10.5 million, lowered from the prior minimum of $10.5 million. Management indicated the range depends primarily on manufacturing completion and shipment timing; no numeric EPS guidance was provided.
The filing reads worse than the one before it.
What came before.
- 10-Q · June 12, 2026
- NeuroOne Medical Technologies Corporation reported Q2 2026 total revenue of $2 million with a gross margin of 53.2% and an EPS of -$0.25. Revenue decreased from $3 million in the previous quarter and from $1 million a…
- 10-Q · May 12, 2026
- In the Q2 2026 filing, NeuroOne Medical Technologies Corporation reported product revenue of $2.39 million, reflecting a 72% year-over-year increase, while the net loss decreased to $2.09 million from nearly $2.27…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NMTC makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever